Table 1 Demographic data, clinical findings, disease activity, quality of life and laboratory investigations of SLE patients:
From: Infection versus disease activity in systemic lupus erythematosus patients with fever
|  | mean ± SD and /or No (%) | SLE patients No = 40 |
|---|---|---|
AGE (years) |  | 31.8 ± 8.5 |
Gender | Female Male | 39 (97.5%) 1 (2.5%) |
Disease activity | SLEDAI-2k score Moderate to severe Activity > 4 Mild activity ≤ 4 | 17.5 ± 10.2 31 (77.5%) 9 (22.5%) |
Health QoL |  | 98.7 ± 5.3 |
Clinical findings | Muco-cuteaneous manifestations Musculoskeletal manifestations Cardiac manifestations Pulmonary manifestations Renal manifestation GIT manifestations CNS manifestations Serositis | 28 (70%) 27(67.5%) 10 (25%) 12 (30%) 14 (35%) 8 (20%) 15 (37.5%) 18 (45%) |
Laboratory investigations | ESR 1sth mm/h CRP (positive) CRP mg/dl ESR/CRP ratio Procalcitonin (positive) Procalcitonin ng/ml ANA (positive) Anti dsDNA (positive) C3 (consumed) C4 (consumed) Pyuria Hematuria Urinary Casts 24 h proteinuria | 43.8 ± 30.5 19 (47.5%) 18 ± 23. 34.8 ± 3 26 (65%) 0.95 ± 0.3 40 (100%) 16 (40%) 10 (25%) 8 (20%) 17 (42.5%) 22 (55%) 4 (10%) 14 (35%) |
Culture | Blood culture Urine culture | 9 (22.5%) 17 (42.5%) |
Medication | Hydroxychloroquine Corticosteroids NSAIDs Azathioprine Cyclophosphamide Mycophenolate mofetetil | 34 (85%) 34 (85%) 6 (15%) 23 (57.5%) 7 (17.5%) 4 (10%) |